150 related articles for article (PubMed ID: 19381450)
1. Response variability to aspirin and one-year prediction of vascular events in patients with stable coronary artery disease.
Addad F; Chakroun T; Abderazek F; Ben-Farhat M; Hamdi S; Dridi Z; Gamra H; Hassine M; Samama MM; Elalamy I
J Thromb Thrombolysis; 2010 Jan; 29(1):108-13. PubMed ID: 19381450
[TBL] [Abstract][Full Text] [Related]
2. Screening for aspirin resistance in stable coronary artery patients by three different tests.
Chakroun T; Addad F; Abderazek F; Ben-Farhat M; Hamdi S; Gamra H; Hassine M; Ben-Hamda K; Samama MM; Elalamy I
Thromb Res; 2007; 121(3):413-8. PubMed ID: 17553552
[TBL] [Abstract][Full Text] [Related]
3. Reduced blood platelet sensitivity to aspirin in coronary artery disease: are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?
Markuszewski L; Rosiak M; Golanski J; Rysz J; Spychalska M; Watala C
Basic Clin Pharmacol Toxicol; 2006 May; 98(5):503-9. PubMed ID: 16635110
[TBL] [Abstract][Full Text] [Related]
4. Aspirin resistance in Indian patients with coronary artery disease and cardiovascular events.
Thomson VS; John B; George P; Joseph G; Jose J
J Postgrad Med; 2009; 55(4):252-6. PubMed ID: 20083870
[TBL] [Abstract][Full Text] [Related]
5. Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response in elderly patients with coronary artery disease.
Liu T; Zhang J; Chen X; Feng X; Fu SW; McCaffrey TA; Liu M
Gene; 2015 Oct; 571(1):23-7. PubMed ID: 26095809
[TBL] [Abstract][Full Text] [Related]
6. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
[TBL] [Abstract][Full Text] [Related]
7. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients.
Chakroun T; Addad F; Yacoub S; Abderrezak F; Gerotziafas GT; Abdelkafi S; Hassine M; Gamra H; Hatmi M; Elalamy I
Genet Test Mol Biomarkers; 2011; 15(7-8):513-6. PubMed ID: 21434767
[TBL] [Abstract][Full Text] [Related]
8. Homocysteine is a novel risk factor for suboptimal response of blood platelets to acetylsalicylic acid in coronary artery disease: a randomized multicenter study.
Karolczak K; Kamysz W; Karafova A; Drzewoski J; Watala C
Pharmacol Res; 2013 Aug; 74():7-22. PubMed ID: 23665469
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effect of aspirin in patients with coronary artery disease.
Grove EL
Dan Med J; 2012 Sep; 59(9):B4506. PubMed ID: 22951204
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of urinary 11-dehydro-thromboxane B
Vasudevan A; Tecson KM; Bennett-Firmin J; Bottiglieri T; Lopez LR; Peterson M; Sathyamoorthy M; Schiffmann R; Schussler JM; Swift C; Velasco CE; McCullough PA
Catheter Cardiovasc Interv; 2018 Oct; 92(4):653-658. PubMed ID: 29193683
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
[TBL] [Abstract][Full Text] [Related]
12. [Correlation between the level of the urinary 11-dehydrothromboxane B2 and the clinical efficacy of aspirin in patients with type 2 diabetes and coronary artery disease].
Liu TF; Zhang JW; Chen XH; Feng XR; Bai ZS; Liu ML
Beijing Da Xue Xue Bao Yi Xue Ban; 2015 Dec; 47(6):920-4. PubMed ID: 26679651
[TBL] [Abstract][Full Text] [Related]
13. The GPIIIa PlA polymorphism and the platelet hyperactivity in Tunisian patients with stable coronary artery disease treated with aspirin.
Abderrazek F; Chakroun T; Addad F; Dridi Z; Gerotziafas G; Gamra H; Hassine M; Elalamy I
Thromb Res; 2010 Jun; 125(6):e265-8. PubMed ID: 20138334
[TBL] [Abstract][Full Text] [Related]
14. Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Larsen SB; Grove EL; Neergaard-Petersen S; Würtz M; Hvas AM; Kristensen SD
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28780510
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity of platelets to adenosine diphosphate in patients with stable cardiovascular disease predicts major adverse events despite antiplatelet therapy.
Christie DJ; Kottke-Marchant K; Gorman RT
Platelets; 2008 Mar; 19(2):104-10. PubMed ID: 17852773
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
[TBL] [Abstract][Full Text] [Related]
17. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
[TBL] [Abstract][Full Text] [Related]
18. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
19. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
Reny JL; De Moerloose P; Dauzat M; Fontana P
J Thromb Haemost; 2008 Mar; 6(3):444-50. PubMed ID: 18194417
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease.
Dannenberg L; Metzen D; Zako S; Pöhl M; Mourikis P; Helten C; Trojovsky K; Naguib D; Konsek D; Knoop B; Ayhan A; Hohlfeld T; Petzold T; Levkau B; Veulemans V; Zeus T; Kelm M; Polzin A
Pharmacology; 2020; 105(1-2):118-122. PubMed ID: 31639801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
